Cancer Genetics has settled its failed merger deal with NovellusDx, paying $1.1 million in cash and $450,000 over nine months. The firm also received $6 million from Interpace Diagnostics related to the recent $23.5 million sale of its biopharma business to Interpace.
Cancer Genetics settles failed merger with NovellusDx
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.